333 related articles for article (PubMed ID: 16175586)
1. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
2. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
3. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
Narayanan NK; Narayanan BA; Reddy BS
Int J Oncol; 2005 Mar; 26(3):785-92. PubMed ID: 15703837
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
[TBL] [Abstract][Full Text] [Related]
6. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
Cancer; 2007 Feb; 109(3):588-97. PubMed ID: 17177201
[TBL] [Abstract][Full Text] [Related]
10. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Anai S; Tanaka M; Shiverick KT; Kim W; Takada S; Boehlein S; Goodison S; Mizokami A; Rosser CJ
J Urol; 2007 May; 177(5):1913-7. PubMed ID: 17437847
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
13. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cyclooxygenase-2 inhibition in an orthotopic murine model of lung cancer for dose-dependent effect.
Sievers EM; Bart RD; Backhus LM; Lin Y; Starnes M; Castanos R; Starnes VA; Bremner RM
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1242-9. PubMed ID: 15942563
[TBL] [Abstract][Full Text] [Related]
15. Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management.
Ghosh R; Graham H; Rivas P; Tan XJ; Crosby K; Bhaskaran S; Schoolfield J; Banu J; Fernandes G; Yeh IT; Kumar AP
Anticancer Res; 2010 Mar; 30(3):857-65. PubMed ID: 20393007
[TBL] [Abstract][Full Text] [Related]
16. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
Wang X; Colby JK; Yang P; Fischer SM; Newman RA; Klein RD
Carcinogenesis; 2008 Jan; 29(1):120-8. PubMed ID: 17942462
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
18. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Sargeant AM; Rengel RC; Kulp SK; Klein RD; Clinton SK; Wang YC; Chen CS
Cancer Res; 2008 May; 68(10):3999-4009. PubMed ID: 18483287
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
Basu GD; Pathangey LB; Tinder TL; Lagioia M; Gendler SJ; Mukherjee P
Mol Cancer Res; 2004 Nov; 2(11):632-42. PubMed ID: 15561779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
